AstraZeneca said Wednesday that a primary analysis of its Stage 3 trial data verified its coronavirus vaccine’s “safety” with a 76?ficacy rate versus symptomatic COVID.
Flashback: The company reported on Monday that a U.S. trial found its vaccine 79?fective, but dealt with backlash after NIAID said Tuesday it may have consisted of details that supplied an “ insufficient view of the efficacy information” in its U.S. results.
Our thought bubble, via Axios’ Caitlin Owens: A 3 portion point difference in effectiveness isn’t much, but the public relations damage to the vaccine induced by the last few days may be difficult to undo.
By the numbers: Upgraded outcomes include information from 190 symptomatic cases, 50 more than the cases studied in the dataset launched Monday.
The new analysis likewise found:
- 100?fectiveness versus serious or vital illness and hospitalization.
- 85?fectiveness against symptomatic COVID-19 in participants ages 65 years and up, a jump from a formerly reported 80%.
What to enjoy: The Food and Drug Administration must go over the information AstraZeneca submits.
The big picture: AstraZeneca already faced debate after more than a lots nations suspended usage of its vaccine in mid-March due to reports of embolism in some people who had actually gotten the shot.
- A European Union firm later on stated there is “ no indication” the vaccine causes blood clots.
No comments:
Post a Comment